BD Announces New Robotics Solution to Automate, Standardize Single-Cell Research
BD (NYSE: BDX) has launched a new high-throughput, robotics-compatible reagent kit for automating single-cell discovery studies. The solution includes the BD® OMICS-One XT WTA Assay and the Hamilton® Microlab™ NGS STAR automated liquid handling platform. This collaboration aims to standardize manual processes and accelerate genetic sequencing material generation.
The automation addresses challenges in DNA library preparation, such as variability, compromised data quality, throughput, high costs, and long turnaround times. It offers increased consistency, efficiency, and reproducibility in experiments, particularly beneficial for oncology and immunology research.
The BD® OMICS-One XT Library Preparation Reagent Kits and Hamilton Microlab NGS STAR platform are now commercially available worldwide.
BD (NYSE: BDX) ha lanciato un nuovo kit di reagenti compatibile con robot ad alta capacità di elaborazione per automatizzare gli studi di scoperta di singole cellule. La soluzione include il BD® OMICS-One XT WTA Assay e la piattaforma automatizzata di gestione dei liquidi Hamilton® Microlab™ NGS STAR. Questa collaborazione mira a standardizzare i processi manuali e accelerare la generazione di materiale per la sequenza genetica.
L'automazione affronta sfide nella preparazione delle librerie DNA, come la variabilità, la compromissione della qualità dei dati, la capacità produttiva, i costi elevati e i lunghi tempi di risposta. Offre una maggiore coerenza, efficienza e riproducibilità negli esperimenti, particolarmente vantaggiosa per la ricerca in oncologia e immunologia.
I kit di reagenti per la preparazione delle librerie BD® OMICS-One XT e la piattaforma Hamilton Microlab NGS STAR sono ora disponibili in commercio in tutto il mondo.
BD (NYSE: BDX) ha lanzado un nuevo kit de reactivos compatible con robots de alto rendimiento para automatizar estudios de descubrimiento de células individuales. La solución incluye el BD® OMICS-One XT WTA Assay y la plataforma automatizada de manejo de líquidos Hamilton® Microlab™ NGS STAR. Esta colaboración tiene como objetivo estandarizar los procesos manuales y acelerar la generación de material de secuenciación genética.
La automatización aborda los desafíos en la preparación de bibliotecas de ADN, como la variabilidad, la calidad de datos comprometida, la capacidad de producción, los altos costos y los largos tiempos de respuesta. Ofrece una mayor consistencia, eficiencia y reproducibilidad en los experimentos, siendo particularmente beneficiosa para la investigación en oncología e inmunología.
Los kits de reactivos para la preparación de bibliotecas BD® OMICS-One XT y la plataforma Hamilton Microlab NGS STAR están ahora disponibles comercialmente en todo el mundo.
BD (NYSE: BDX)는 단일 세포 발견 연구를 자동화하기 위한 로봇 호환 고처리량 시약 키트를 출시했습니다. 이 솔루션에는 BD® OMICS-One XT WTA Assay와 Hamilton® Microlab™ NGS STAR 자동 액체 취급 플랫폼이 포함됩니다. 이 협력의 목표는 수동 프로세스를 표준화하고 유전적 서열 생성의 속도를 높이는 것입니다.
자동화는 DNA 라이브러리 준비 시의 변동성, 데이터 품질 저하, 처리량, 높은 비용 및 긴 소요 시간과 같은 문제를 해결합니다. 실험에서 일관성, 효율성 및 재현성을 높일 수 있으며, 특히 종양학 및 면역학 연구에 유리합니다.
BD® OMICS-One XT 라이브러리 준비 시약 키트와 Hamilton Microlab NGS STAR 플랫폼은 현재 전 세계적으로 상용화되어 있습니다.
BD (NYSE: BDX) a lancé un nouveau kit de réactifs haut débit compatible avec la robotique pour automatiser les études de découverte de cellules uniques. La solution comprend le BD® OMICS-One XT WTA Assay et la plateforme de manipulation des liquides automatisée Hamilton® Microlab™ NGS STAR. Cette collaboration vise à standardiser les processus manuels et à accélérer la génération de matériel de séquençage génétique.
L'automatisation s'attaque aux défis de la préparation des bibliothèques d'ADN, tels que la variabilité, la qualité des données compromise, le débit, les coûts élevés et les longs délais de traitement. Elle offre une meilleure cohérence, efficacité et reproductibilité dans les expériences, ce qui est particulièrement bénéfique pour la recherche en oncologie et en immunologie.
Les kits de réactifs pour la préparation des bibliothèques BD® OMICS-One XT et la plateforme Hamilton Microlab NGS STAR sont d'ores et déjà disponibles sur le marché dans le monde entier.
BD (NYSE: BDX) hat ein neues hochdurchsatzfähiges, robotik-kompatibles Reagenzkit zur Automatisierung von Einzelzellen-Entdeckungsstudien auf den Markt gebracht. Die Lösung umfasst den BD® OMICS-One XT WTA Assay und die automatisierte Flüssigkeitsverarbeitungsplattform Hamilton® Microlab™ NGS STAR. Diese Zusammenarbeit zielt darauf ab, manuelle Prozesse zu standardisieren und die Erzeugung von genetischem Sequenzmaterial zu beschleunigen.
Die Automatisierung begegnet Herausforderungen in der DNA-Bibliotheksvorbereitung, wie Variabilität, beeinträchtigte Datenqualität, Durchsatz, hohe Kosten und lange Durchlaufzeiten. Sie bietet erhöhte Konsistenz, Effizienz und Reproduzierbarkeit in Experimenten, was insbesondere für die Onkologie- und Immunologie-Forschung von Vorteil ist.
Die BD® OMICS-One XT Bibliotheksvorbereitungs-Reagenz-Kits und die Hamilton Microlab NGS STAR-Plattform sind jetzt weltweit kommerziell verfügbar.
- Launch of new high-throughput, robotics-compatible reagent kits for single-cell discovery studies
- Collaboration with Hamilton to integrate automation into existing workflows
- Potential for increased consistency and efficiency in large-scale studies
- Standardization of manual processes, reducing variability and human error
- Global commercial availability of the new product line
- None.
Insights
The launch of BD's automation-ready reagent kits for single-cell research represents a significant advancement in genomic sequencing workflows. This innovation addresses key pain points in the industry:
- Standardization of manual processes, reducing variability
- Increased efficiency and throughput for large-scale studies
- Potential for cost reduction and faster turnaround times
The collaboration with Hamilton Robotics leverages existing infrastructure in many labs, facilitating easier adoption. This could lead to accelerated research in oncology and immunology, potentially impacting drug discovery and personalized medicine.
However, the immediate financial impact on BD may be While this product enhances BD's competitive position in the growing single-cell analysis market, it's likely to be a gradual contributor to revenue rather than a game-changer. Investors should monitor adoption rates and any follow-on products in this automation-ready family to gauge long-term potential.
Automation-Ready Reagents Used with the Hamilton Robotics Liquid-Handler Streamlines and Helps Accelerate Lab Work Leading to Genomic Sequencing
The automated solution from the BD and
In single-cell discovery studies involving genetic material, constructing preparatory material otherwise called "DNA libraries" is an essential early step. Historically, such preparations have been labor-intensive and time-consuming processes, with numerous manual steps that often lead to variability of results, compromised data quality, limited throughput, high cost and long turnaround times.
"By automating the complex library preparation process, researchers can scale their sample throughput and expect more consistent results, minimizing the variability introduced by manual procedures," said Steve Conly, worldwide president of BD Biosciences. "This standardization is crucial for the reproducibility of experiments, which is a cornerstone of scientific research. The integration of
Matt
The BD® OMICS-One XT Library Preparation Reagent Kits and Hamilton Microlab NGS STAR automated liquid handling platform and applications are commercially available globally. The robotics liquid-handling platform is available for purchase from
About BD
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X (formerly Twitter) @BDandCo or Instagram @becton_dickinson.
Contacts:
Media: Investors:
Troy Kirkpatrick Adam Reiffe
VP, Public Relations Sr. Director, Investor Relations
858.617.2361 201.847.6927
troy.kirkpatrick@bd.com adam.reiffe@bd.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/bd-announces-new-robotics-solution-to-automate-standardize-single-cell-research-302274570.html
SOURCE BD (Becton, Dickinson and Company)
FAQ
What new product has BD (BDX) launched for single-cell research?
How does BD's new robotics solution benefit single-cell research?
When did BD (BDX) announce the launch of its new robotics solution?
What are the main advantages of BD's (BDX) new automated solution for genomics research?
